Legend Biotech (LEGN) Competitors $42.07 -1.06 (-2.46%) (As of 11/29/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LEGN vs. BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, PCVX, and CTLTShould you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Legend Biotech vs. BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Vaxcyte Catalent BioNTech (NASDAQ:BNTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Do analysts rate BNTX or LEGN? BioNTech currently has a consensus target price of $138.67, suggesting a potential upside of 17.13%. Legend Biotech has a consensus target price of $81.46, suggesting a potential upside of 93.63%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.81Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, BNTX or LEGN? BioNTech has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Do insiders and institutionals have more ownership in BNTX or LEGN? 15.5% of BioNTech shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor BNTX or LEGN? In the previous week, BioNTech had 23 more articles in the media than Legend Biotech. MarketBeat recorded 31 mentions for BioNTech and 8 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.13 beat BioNTech's score of 0.60 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BNTX or LEGN more profitable? BioNTech has a net margin of -15.16% compared to Legend Biotech's net margin of -66.92%. BioNTech's return on equity of -2.35% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-15.16% -2.35% -2.05% Legend Biotech -66.92%-29.69%-19.45% Does the MarketBeat Community believe in BNTX or LEGN? BioNTech received 57 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 70.80% of users gave Legend Biotech an outperform vote while only 45.51% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformBioNTechOutperform Votes13745.51% Underperform Votes16454.49% Legend BiotechOutperform Votes8070.80% Underperform Votes3329.20% Which has better earnings and valuation, BNTX or LEGN? BioNTech has higher revenue and earnings than Legend Biotech. BioNTech is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$4.13B6.87$1.01B-$2.10-56.38Legend Biotech$285.14M27.07-$518.25M-$0.95-44.28 SummaryBioNTech beats Legend Biotech on 10 of the 19 factors compared between the two stocks. Ad TradingTips3 Dirt-Cheap Stocks You Can’t Afford to Ignore Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here. Get Legend Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEGN vs. The Competition Export to ExcelMetricLegend BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.72B$7.17B$5.55B$8.93BDividend YieldN/A7.97%5.36%4.04%P/E Ratio-44.285.6875.3814.63Price / Sales27.07352.801,304.93166.16Price / CashN/A62.0544.5838.62Price / Book6.9210.777.436.72Net Income-$518.25M$153.05M$120.35M$225.41M7 Day Performance2.76%4.19%3.95%3.06%1 Month Performance-5.16%-1.72%1.59%9.47%1 Year Performance-29.87%35.08%36.88%29.95% Legend Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEGNLegend Biotech2.3807 of 5 stars$42.07-2.5%$81.46+93.6%-30.8%$7.72B$285.14M-44.281,800Short Interest ↑News CoveragePositive NewsBNTXBioNTech2.1453 of 5 stars$118.21+4.5%$138.79+17.4%+17.9%$28.34B$4.13B-54.956,133Analyst ForecastShort Interest ↑TEVATeva Pharmaceutical Industries2.4783 of 5 stars$16.86-1.5%$19.67+16.6%+70.8%$19.10B$15.85B-19.8737,851Options VolumeAnalyst RevisionBGNEBeiGene2.3029 of 5 stars$189.54-0.5%$247.07+30.4%+15.0%$18.46B$2.46B-22.9410,600Insider TradeShort Interest ↓News CoverageMRNAModerna4.6512 of 5 stars$43.81+6.6%$84.00+91.7%-44.6%$16.86B$6.85B-7.665,600Analyst ForecastHigh Trading VolumeVTRSViatris2.4053 of 5 stars$13.45+0.6%$13.33-0.9%+42.6%$16.05B$15.43B0.0038,000Short Interest ↓SMMTSummit Therapeutics2.9046 of 5 stars$18.99-0.1%$34.75+83.0%+809.4%$14.00B$700,000.00-67.89105Positive NewsGMABGenmab A/S4.5211 of 5 stars$20.76+0.5%$45.20+117.7%-32.0%$13.74B$2.39B20.052,204High Trading VolumeRDYDr. Reddy's Laboratories1.4596 of 5 stars$14.32+0.8%$17.00+18.7%+1.1%$11.95B$3.35B22.6827,048Analyst RevisionNews CoveragePCVXVaxcyte3.187 of 5 stars$91.56+3.4%$147.50+61.1%+82.2%$11.41BN/A0.00160Positive NewsCTLTCatalent3.3502 of 5 stars$60.98flat$63.40+4.0%+57.3%$11.07B$4.38B-26.9916,900Short Interest ↑ Related Companies and Tools Related Companies BNTX Alternatives TEVA Alternatives BGNE Alternatives MRNA Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives PCVX Alternatives CTLT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LEGN) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
